

	Indication/Target	Program	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Trial Name / Collaborator
Late stage	<b>NSCLC (2<sup>nd</sup>/3<sup>rd</sup> line)</b>	Plinabulin + Docetaxel						DUBLIN-3
	<b>CIN Prevention</b>	Plinabulin + Pegfilgrastim						PROTECTIVE-1 & PROTECTIVE-2
Investigator Initiated Trials	<b>SCLC (2<sup>nd</sup>/3<sup>rd</sup> line)</b>	Plinabulin + PD-1 + CTLA-4						Bristol Myers Squibb RUTGERS
	<b>NSCLC (2<sup>nd</sup>/3<sup>rd</sup> line PD-1 failed)</b>	Plinabulin + PD-1 + Docetaxel						MERCK
	<b>7 cancers (PD-1/PD-L1 failed)</b>	Plinabulin + PD-1/PD-L1 + Radiation						THE UNIVERSITY OF TEXAS <del>MD Anderson</del> Cancer Center
	<b>AHCT (hematopoietic stem cell transplantation) in Multiple myeloma</b>	Plinabulin + Pegfilgrastim						Memorial Sloan Kettering Cancer Center
	<b>Preclinical assets</b>	BPI-002, BPI-003, BPI-004						
Early Stage	<b>KRAS and additional targets</b>	Targeted Protein Degradation (TPD) Molecule Glue Platform						SEED THERAPEUTICS
	<b>Multiple</b>	TPD (Molecular Glue)						Lilly

BeyondSpring Subsidiaries: 1) Dalian Wanchunbulin Pharmaceuticals Ltd., which owns China rights to Plinabulin, and 2) Seed Therapeutics, a target protein degradation company.